These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 17391168)

  • 1. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.
    Lund SS; Tarnow L; Stehouwer CD; Schalkwijk CG; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag A
    Diabetes Obes Metab; 2007 May; 9(3):394-407. PubMed ID: 17391168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
    Lund SS; Tarnow L; Frandsen M; Nielsen BB; Hansen BV; Pedersen O; Parving HH; Vaag AA
    BMJ; 2009 Nov; 339():b4324. PubMed ID: 19900993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Stehouwer CD; Schalkwijk CG; Teerlink T; Gram J; Winther K; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 May; 158(5):631-41. PubMed ID: 18426821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
    Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
    J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
    Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
    Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial.
    Gerstein HC; Garon J; Joyce C; Rolfe A; Walter CM
    Diabet Med; 2004 Nov; 21(11):1200-3. PubMed ID: 15498086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
    Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
    Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide versus glyburide: a one-year comparison trial.
    Marbury T; Huang WC; Strange P; Lebovitz H
    Diabetes Res Clin Pract; 1999 Mar; 43(3):155-66. PubMed ID: 10369424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients.
    Soegondo S; Subekti I; Luthariana L
    Acta Med Indones; 2004; 36(3):142-7. PubMed ID: 15557683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.
    Wang W; Bu R; Su Q; Liu J; Ning G
    Expert Opin Pharmacother; 2011 Dec; 12(18):2791-9. PubMed ID: 21780853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
    Raskin P; McGill J; Saad MF; Cappleman JM; Kaye W; Khutoryansky N; Hale PM;
    Diabet Med; 2004 Apr; 21(4):329-35. PubMed ID: 15049934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
    Moses R; Slobodniuk R; Boyages S; Colagiuri S; Kidson W; Carter J; Donnelly T; Moffitt P; Hopkins H
    Diabetes Care; 1999 Jan; 22(1):119-24. PubMed ID: 10333912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
    Wolffenbuttel BH; Landgraf R
    Diabetes Care; 1999 Mar; 22(3):463-7. PubMed ID: 10097930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
    Van Gaal LF; Van Acker KL; De Leeuw IH
    Diabetes Res Clin Pract; 2001 Sep; 53(3):141-8. PubMed ID: 11483229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
    Esposito K; Giugliano D; Nappo F; Marfella R;
    Circulation; 2004 Jul; 110(2):214-9. PubMed ID: 15197140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repaglinide in combination therapy with metformin in Type 2 diabetes.
    Moses R
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S136-9. PubMed ID: 10522839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.